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Abstract

The aim of this work is to develop dual-functional scaffolds for bone tissue regeneration and local
antibiotic delivery applications. In this respect, bioresorbable bredigite (Ca7MgSi4O16) porous scaffolds
were fabricated by a foam replica method, loaded with vancomycin hydrochloride and encapsulated in
poly lactic-co-glycolic acid (PLGA) coatings. Field emission scanning electron microscopy, Archimedes
porosimetry and Fourier-transform infrared spectroscopy were used to characterize the structure of
the scaffolds. The drug delivery kinetics and cytocompatibility of the prepared scaffolds were also
studied in vitro. The bare sample exhibited a burst release of vancomycin and low biocompatibility with

respect to dental pulp stem cells based on the MTT assay due to the fast bioresorption of bredigite.
While keeping the desirable characteristics of pores for tissue engineering, the biodegradable PLGA
coatings modified the drug release kinetics, buffered physiological pH and hence improved the cell
viability of the vancomycin-loaded scaffolds considerably.
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1. Introduction

One of the major complications of bone tissue engineering after implantation is bacterial bone
infection or osteomyelitis, which can cause severe pain in patients and demand a high cost of
treatment (Hetrick and Schoenfisch, 2006, Lucke et al., 2003, Shirtliff and Mader, 2000). To overcome
this problem, systematic drug delivery is a prevalent method with several disadvantages like the
possibility of high systemic toxicity and longer hospitalization. In contrast, local drug delivery is a
suitable alternative that lacks the aforementioned drawbacks. These devices provide a sustained
concentration of drugs needed for the inhibition of pathogens at the intended site in a prolonged and
controlled fashion with no or minimal drug concentration in the systemic circulation (Jain, 2008,
Marwah et al., 2016, Sankar et al., 2011). Fortunately, tissue-engineering scaffolds have the ability to
act as the matrix of local drug delivery systems for bone infection treatment at the implantation site. In
this regard, chitosan-coated bioactive glass scaffolds loaded with gatifloxacin and fluconazole
(Soundrapandian et al., 2010), gelatin-hydroxyapatite scaffolds impregnated with ciprofloxacin
(Krishnan et al., 2015) and calcium sulfate scaffolds loaded with tobramycin (Ferguson et al., 2014) are
noticeable.
In this study, bredigite (Ca7MgSi4O16) was chosen to fabricate the foundation of a dual-functional
system with the aim of bone tissue regeneration and local drug delivery. From the viewpoint of
mechanical properties, it is well-established that Mg-Ca silicates including bredigite are superior to
apatites and bioglasses which are commonly used for implantation (Schumacher et al., 2014, Wu et al.,
2007). As well as the direct role of Ca in bone-related processes, the presence of Mg and Si in this
group of bioceramics is beneficial for some cellular processes and human metabolism, including bone

healing processes (Diba et al., 2014, Diba et al., 2012). In the orthorhombic structure of bredigite, the
most abundant cation is Ca2+, which provides high resorbability due to the lower activation energy of
Ca-O bond for hydrolysis than Mg-O bond (Wu and Chang, 2007a). Among the variety of antibiotics,
vancomycin was also selected to treat osteomyelitis because this is a very active glycopeptide
antibiotic against staphylococcus aureus. In addition, this has the least deleterious effect on the
function of osteoblasts and skeletal cells compared to other antibiotics used in the treatment of
osteomyelitis like ciprofloxacin and tobramycin (Antoci et al., 2007, Edin et al., 1996).
The adsorption of drugs on drug delivery devices with weak physical bonds like the van der Waals type,
rather than a chemical interaction, gives rise to a burst release of the drug during implantation. This is
disadvantageously accompanied by the release of the entire drug before controlling the infection and a
detrimental effect on biocompatibility due to the high concentration of the drug around the
surrounding tissue (Huang and Brazel, 2001). It is noticeable that in the treatment of osteomyelitis
caused by staphylococcus aureus, vancomycin should be released continually through 4–6 weeks at
concentrations exceeding the minimum inhibitory concentration (MIC, 0.75–2 μg/ml) and minimum
bactericidal concentration (MBC, 8 μg/ml) (Coudron et al., 1987, Gold and Moellering, 1996, Mason et
al., 2009). MIC is the minimal concentration of a drug which prevents the visible growth of a bacterium
and MBC is the lowest antibacterial density necessary to kill the bacterium. On the other hand, the
high bioresorption rate of bredigite leads to metabolic alkalosis due to the high concentration of
alkaline ionic (Ca2+ and Mg2+) around the surrounding tissue followed by the reduction of hydrogen
ions (H+) outside the normal range (Galla, 2000). The use of polymer coatings is a promising approach
to control both the resorption rate of scaffolds and the drug release rate of these devices.
To the best of our knowledge, there are no reports in the literature on the use of bredigite scaffolds as
the matrix of drugs, which is the subject of this work. In this regard, to control the burst release of
vancomycin and high physiological pH caused by the fast bioresorption of bredigite, bredigite scaffolds
were coated with poly lactic-co-glycolic acid (PLGA). PLGA is a biodegradable synthetic aliphatic
polyester made from the monomers of polylactide (PLA) and polyglycolide (PGA) with successful
consequences as coating for drug delivery and tissue-engineering applications (Bose et al., 2018, Jadidi
and Salahinejad, 2020, Khojasteh et al., 2016, Maurmann et al., 2017, Olalde et al., 2013, Su et al.,
2019, Zamboni et al., 2017). Alternatively, polycaprolactone (PCL) is another polymer which has been
extensively used for biomedical applications due to suitable biodegradability and nontoxicity (Park et
al., 2012). However, PCL with a considerable biostability is postulated to disadvantageously suppress
the appropriate bioresorbability of bredigite. The use of PLGA is also hypothesized to buffer the
metabolic alkalosis phenomenon caused by the fast bioresorption of bredigite (Jadidi and Salahinejad,
2020, Keihan et al., 2020) since the degradation of this biopolymer acidifies the physiological medium
(Zhao et al., 2011, Zhao et al., 2012).

2. Experimental procedures
2.1. Materials

Tetraethyl orthosilicate ((C2H5O)4Si, TEOS, Merck, Germany, Purity > 98%), magnesium nitrate
hexahydrate (Mg(NO3)2·6H2O, Merck, Germany, Purity > 98%), calcium nitrate tetrahydrate
(Ca(NO3)2·4H2O, Merck, Germany, Purity > 98%), and nitric acid (HNO3, 2 M, Merck, Germany) were

used for the sol–gel synthesis of bredigite. The drug and coating materials were vancomycin
hydrochloride (C66H75Cl2N9O24, Sigma Aldrich) and PLGA (5004A, lactide/glycolide ratio of 50:50,
molecular weight = 44 kDa, acid-terminated, acid number: min 3 mg KOH/g, Corbion, Netherlands),
respectively.

2.2. Synthesis of powder used for scaffolding

A sol–gel technique similar to Refs. (Jadidi and Salahinejad, 2020, Wu and Chang, 2007b, Wu et al.,
2007) was used for the synthesis of bredigite. For the preparation of 1.000 g bredigite powder,
1.000 ml TEOS, 0.651 ml distilled water and 0.361 ml nitric acid were stirred at room temperature for
30 min. Thereafter, 0.289 g magnesium nitrate hexahydrate and 1.864 g calcium nitrate tetrahydrate
were added to the solution and again stirred for 5 h. The solution was then maintained at 60 °C for
1 day, dried at 120 °C for 2 days and calcined at 700 °C for 3 h.

2.3. Fabrication of bredigite scaffolds

In order to fabricate bredigite scaffolds, the sacrificial foam replication method was employed. For this
purpose, the calcined powder was suspended in a sodium alginate aqueous solution (3% w/w) with the
bredigite/sodium alginate solution mass ratio of 1:3 under sonication for 3 min. Polyurethane foam
templates (density: 25 ppi, porosity > 97%) were cut in a dimension ~10 × 10 × 10 mm3, immersed in a
glass beaker containing the bredigite slurry and then forced by a compressed air flow to eliminate the
extra slurry. After drying at 60 °C for 12 h, the impregnated foams were heated at 300 °C for 1 h for the
removal of the urethane struts and then at 1350 °C for 3 h for sintering at the heating rate of 3 °C/min.
X-ray diffraction analyses have previously confirmed the successful synthesis of bredigite via this
processing route (Jadidi and Salahinejad, 2020, Wu and Chang, 2007b, Wu et al., 2007).

2.4. Drug loading in scaffolds

For the drug loading into the scaffolds, vancomycin hydrochloride was dissolved in distilled water with
the concentration of 0.31 mg/ml. The scaffolds were maintained in the vancomycin solution with the
ratio of 5 mg/ml for 24 h and then dried in air for 24 h.

2.5. PLGA coating of scaffolds

For the PLGA coating of the vancomycin-loaded scaffolds, 5 and 10% w/v solutions of PLGA and
acetone were prepared at room temperature. Thereafter, the scaffolds were dipped into 10 ml of the
PLGA solution for 3 sec and dried at 60 °C for 2 h for the solvent removal.

2.6. Structural characterization

The morphology of the samples was analyzed by field emission scanning electron microscopy (FESEM,
MIRA3 TESCAN, Czech Republic, accelerating voltage = 15 kV) after gold sputtering. Porosimetry was
also performed using the water Archimedes method, according to the following formula (Mirhadi et al.,
2012):(1)
where P is the pore percentage, W1 and W2 are the weight of the scaffolds before and after immersion
in water, respectively, and W3 is the weight of the suspended scaffolds.

Fourier-transform infrared spectroscopy (FTIR, Thermo Nicolet, Avatar, USA) was also conducted on
the milled scaffolds in the spectral range of 3600–400 cm−1 with the resolution of 4 cm−1 in a moisturefree environment at 25 °C.

2.7. Drug release analysis

In order to determine the in vitro release profile of vancomycin, the bare and PLGA-coated bredigite
scaffolds impregnated with vancomycin were immersed into a glass bottle containing 20 ml phosphate
buffered saline (PBS) with the ratio of 4 mg/ml at pH of 7.4 and 37 °C. At each predetermined time
point, 3 ml of the solution was taken out and replaced with 3 ml of the fresh PBS solution. The amount
of vancomycin in the solution was investigated by a UV spectrophotometer (UV–1100, MAPADA
INSTRUMENT, Shanghai, China) at the wavelength of 280 nm with three repetitions. To calculate the
accumulative release percentage of the drug, the total amount of vancomycin loaded into the scaffolds
was also measured after the scaffolds were completely degraded in the medium. In order to establish
the calibration curve of measurements, five concentrations of vancomycin in the range of 1–20 μg/ml
were chosen. According to the Beer-Lambert law (Thomas, 1996), the following calibration equation
was found with the correlation coefficient of R2 = 0.998 and used:(2)

2.8. Physiological pH evaluation

The variations of physiological pH due to exposure to the scaffolds were investigated by immersing
them in the simulated body fluid (SBF) at 37 °C for 7 days using an electrolyte type pH meter (PHS-2C,
Jingke Leici Co., Shanghai, China) with three repetitions. To do so, the scaffold/SBF ratio of 1:200 g/ml
(Wu et al., 2006, Wu et al., 2011, Wu et al., 2010) was used.

2.9. Biocompatibility assessments

The MTT assay was conducted to assess the cytocompatibility of the prepared scaffolds of
3 × 3 × 3 mm3 in size. The scaffolds were sterilized via exposure to UV radiation for 2 h. 3500 human
dental pulp stem cells obtained from National Cell Bank of Iran were seeded on each set of the
scaffolds with three repeatations in a 96-well culture plate with the scaffold-free cells-containing
medium as the control and were then incubated at 37 °C under 5% CO2 with Dulbecco‘s modified Eagle
media (DMEM) supplemented with 10% fetal bovine serum (FBS, Gibco, USA) for 1, 3 and 7 days. The
cytotoxicity assessment was done by using 3-[4, 5-dimethylthiazol-2-y1]-2, 5 diphenyltetrazolium
bromide (MTT, Sigma, USA) colorimetric assay based on the instructions of Ref. (Shahrouzifar et al.,
2019). For this purpose, the culture medium was first removed, and then 100 μL of the MTT solution
(5 mg/ml) was added to each well and incubated for 2 h at 37 °C under 5% CO2. Then, the medium was
removed, and formazan precipitates were dissolved in dimethyl sulfoxide (Sigma, USA). The optical
density of viable cells was measured by a microplate reader (ChroMate-4300, FL, USA) at the
wavelength of 545 nm. One-way analysis of variance with a statistical significance level less than 5% (pvalue < 0.05) was used to compare the cytocompatibility data.
The cell morphology on the optimal scaffold was also evaluated according to the protocol of Ref.
(Shahrouzifar and Salahinejad, 2019). Briefly, 20,000 cells were seeded onto the sterilized scaffold and
incubated in DMEM, 10% FBS, 100 IU/mL penicillin, and 100 IU/mL streptomycin. After 24 h of cell
seeding, cells were fixed on the scaffold by 300 µL glutaraldehyde (2.5% in PBS) for 3 h at room
temperature, then washed with PBS for 5 min and dehydrated in ascending ethanol series (30, 50, 70,

80, 90, and 100%). Finally, the sample was coated with a thin layer of gold and studied by electron
microscopy.

3. Results and discussion
3.1. Structural analyses

The FESEM micrograph of the powder calcined at 700 °C used as the feedstock of scaffolding is shown
in Fig. 1a, revealing highly agglomerated nanoparticles of almost 25 nm in size. Fig. 1b, c and d present
the macrograph and micrograph of the scaffolds sintered at 1350 °C, consisting of irregular shaped
particles of about 1–10 μm in size. The mean size of pores inside the struts is 3 μm, while the struts
form pores of almost 200–1000 μm in size which are essential for bone tissue engineering. It would be
worth mentioning that natural cancellous and cortical bones have 75–85% and 5–10% porosity levels
with 300–600 and 10–50 µm sizes, respectively (Lee et al., 2012, Weiner and Wagner, 1998).

Fig. 1. FESEM micrograph of the sol–gel derived powder calcined at 700 °C (a), macrograph of the scaffold
sintered at 1350 °C (b) and FESEM micrographs of the sintered scaffold in two magnifications (c, d).

Fig. 2 reveals the FESEM micrograph of the bare and PLGA-coated bredigite scaffolds. As well as the
preservation of pores interconnectivity (Fig. 2a, c and e), the filling of fine pores of the struts as the
drug loading matrix is evident after PLGA coating (Fig. 2d and f). Based on the Archimedes porosimetry
method, the mean porosity levels of about 90, 82 and 77% were also measured for the bare, bredigite5% PLGA and bredigite-10% PLGA scaffolds, respectively, where all are in the desired range of tissueengineering scaffolds. On the contrary, 15% PLGA coating has been reported to disadvantageously
block the pores of the scaffold (Jadidi and Salahinejad, 2020); thus, this sample is not considered in this

study. In addition, the thickness of the PLGA coatings deposited by the polymer concentrations of 5
and 10% is measured to be almost 7 and 16 μm, respectively (Fig. 3). It is also noticeable that the mean
compressive mechanical strength of the bare, 5% PLGA-coated and 10% PLGA-coated bredigite
scaffolds, albeit without any drug impregnation, is almost 0.3, 1.2 and 1.7 MPa, respectively (Jadidi and
Salahinejad, 2020), where the strength of the PLGA-coated scaffolds is acceptable for bone tissueengineering applications.

Fig. 2. FESEM micrographs of the bare (a, b), 5% PLGA-coated (c, d) and 10% PLGA-coated (e, f) bredigite
scaffolds in two magnifications.

Fig. 3. Cross-sectional FESEM micrographs of the 5% (a, b) and 10% (c, d) PLGA-coated bredigite struts, where A,
B and C represent the PLGA coating surface, bredigite strut cross section and PLGA coating cross section,
respectively.

In order to confirm the formation of bredigite, the incorporation of vancomycin and the deposition of
PLGA, the FTIR spectroscopy on the samples was used (Fig. 4). For the ceramic scaffold before
impregnating with the drug and PLGA (Fig. 4a), the characteristic peaks of 1100–1000, 960 and
873 cm−1 are assigned to the SiO4 tetrahedron stretching. The peak of 616 cm−1 is related to the SiO4
tetrahedron bending. Also, 516 and 553 cm−1 are attributed to the O–Mg–O bending and Ca–O
stretching vibrations, respectively. These assignments are in good agreement with the functional
groups of bredigite (Khandan and Ozada, 2017, Mirhadi et al., 2012, Rahmati et al., 2018). For the
vancomycin-loaded scaffolds (Fig. 4b and c), the broad peak of 3406 cm−1 is attributed to the stretching
vibration of the hydroxyl group. Also, peaks at 1655, 1504 and 1231 cm−1 are assigned to the
vibrational modes of C O, aromatic C C and phenolic cycle, respectively (Cerchiara et al., 2015,
Ordikhani and Simchi, 2014, Yao et al., 2013), proving the successful incorporation of vancomycin into
the scaffolds. The lack of any shifts in the absorption bands of vancomycin suggests that no chemical
interactions occur between the drug and other substances, as an evidence for the physical adsorption
of the drug. Also, for the PLGA-coated sample (Fig. 4c), the characteristic peaks of PLGA are identified
at 1182 and 1089 cm−1 (C O C stretching), 1752 cm−1 (C O stretching) and 1454 cm−1 (C H
stretching), which are compatible with the FTIR assignments of Refs. (Akl et al., 2016, Meng et al.,
2010, Singh et al., 2014, Wang et al., 2019) for this aliphatic polyester.

Fig. 4. FTIR spectra of the bare vancomycin-free (a), bare vancomycin-loaded (b) and PLGA-coated vancomycinloaded (c) bredigite scaffolds.

3.2. Drug delivery assessments

The accumulative amount and percentage profiles of vancomycin released from the scaffolds are
illustrated in Fig. 5. The percentages were calculated with respect to the total loaded content of
vancomycin which was 66.6 ± 2.1% of the drug dissolved in the solution. For the bare scaffold, a burst
release of vancomycin is detected within 9 h, so that about 94.7 ± 2.5% of the loaded vancomycin level
is released. Nevertheless, after coating of the scaffolds with PLGA, the burst release is beneficially
declined to the first 6 h with only 21.0 ± 2.9 and 18.5 ± 1.8% of the loaded drug amount for the
bredigite-5% PLGA and bredigite-10% PLGA scaffolds, respectively. These modified levels of the burst
release in the first 6 h of implantation, called “decisive period”, are essential to prevent the adhesion
of bacteria and thereby inhibit infections (Linke and Goldman, 2011, Poelstra et al., 2002).

Fig. 5. Concentration (a) and percentage (b) of vancomycin released from the different scaffolds.

In accordance with Fig. 5, after the initial burst release of the drug from the scaffolds, the release rate
of vancomycin decreases and a sustained release is followed for the coated scaffolds. Typically, after
one day of exposure, vancomycin is almost completely released from the bare scaffold, which is
insufficient for the antibiotic therapy of osteomyelitis (Ford and Cassat, 2017, Long et al., 2016, Pande
et al., 2015). In a similar study, Yao et al. (2013) investigated the vancomycin release behavior of bare
and coated bioglass scaffolds and showed that vancomycin was released completely from the bare
scaffold in less than 24 h. In contrast, only 33.3 ± 4.6 and 29.6 ± 2.6% of the initial loaded drug amount
are desirably released from the 5 and 10% PLGA-coated bredigite scaffolds, respectively. Typically,
after 7 days of immersion, nearly 6.16 ± 2.2 and 52.77 ± 2.7% of the drug still remain in the bredigite5% PLGA and bredigite-10% PLGA scaffolds, respectively. The different kinetics of vancomycin release
from the PLGA-coated samples is attributed to the different encapsulation modes of the struts with the
PLGA deposits (Fig. 2d and f) and the different thicknesses of the coatings (Fig. 3). It is also worth
mentioning that the drug release contents from the PLGA-coated scaffolds over the whole study period
are above the MIC and MBC levels of vancomycin against staphylococcus aureus (0.75–2 and 8 μg/ml,
respectively (Coudron et al., 1987, Mason et al., 2009)), which is desirable for treating osteomyelitis.

3.3. Investigation of physiological pH variations

Fig. 6 depicts the pH value of the SBF during exposure to the scaffolds as a
biodegradation/bioresorption-related evaluation. A sharp increase of pH from 7.47 ± 0.02 to
9.17 ± 0.08 is observed for the bare bredigite scaffold during 7 days of soaking. Due to the domination
of Ca in the bredigite structure (Ca7MgSi4O16) and the high affinity of the Ca-O bond for hydrolysis, the
bioresorption rate of bredigite is very high (Keihan and Salahinejad, 2020, Wu and Chang, 2007a, Zirak
et al., 2020). This results in a high local concentration of Ca+2 and Mg+2 ions in the surrounding
biological environment. Accordingly, the activation of the ion exchange mechanism reduces the
hydrogen ion concentration of the environment and thereby enhances pH. Regarding the bare scaffold
impregnated with the drug, the presence of vancomycin despite an acidic character (Marshall, 1965)
could not significantly decline physiological pH, due to the low concentration of the drug released into
the medium. In contrast, the PLGA coating of the vancomycin-loaded scaffolds effectively considerably
buffers pH. According to Fig. 6, the buffering effect is enhanced by increasing the PLGA concentration
from 5% to 10% due to the following reasons:
i.
ii.

the release rate of the cations from the bredigite scaffolds is somewhat restricted with the
increase of the coating thickness, where the PLGA coatings act as a physical barrier.
the amount of the acidic coproducts of PLGA (i.e. glycolic and lactic acids) released due to
hydrolytic biodegradation is enhanced by increasing the content of PLGA.

Fig. 6. pH variations of the SBF in contact with the different scaffolds.

3.4. Biocompatibility evaluations

The MTT assay results of the cells cultured on the different scaffolds are indicated in Fig. 7, with the
significance level of less than 5% (p-value < 0.05). Over the entire periods of culture, the
cytocompatibility of the samples with respect to dental pulp stem cells ranks as follows: vancomycinloaded 10% PLGA-coated bredigite > vancomycin-loaded 5% PLGA-coated > bredigite > vancomycinloaded bredigite. Essentially, the fast bioresorption of bredigite leads to high physiological pH (Fig. 6)
and the high concentration of Ca2+ released into the medium (Peshwa et al., 1993, Zhivotovsky and
Orrenius, 2011), which are responsible for the relatively low cell viability on the bredigite scaffold, in
agreement with Ref. (Wu and Chang, 2007a). The impregnation of the bredigite scaffold with the
antibiotic drug under the bare conditions further decreases the cell cytocompatibility, due to the burst
release of vancomycin in the medium (Fig. 5). Consistently, the detrimental influence of high
vancomycin dosages on biocompatibility has been previously pointed out (Bakhsheshi-Rad et al.,
2017). The controlling effects of the PLGA coatings on the burst release of the drug (Fig. 5), bredigite
bioresorption and physiological pH (Fig. 6) cause the higher cytocompatibility of the coated scaffolds.
This is supported by the fact that the cell viability is further improved by increasing the PLGA
concentration from 5% to 10%.

Fig. 7. MTT results of the cell cultures on the different scaffolds, where *, Δ, and � demonstrate significant
differences with respect to the control, bare vancomycin-free bredigite, vancomycin-loaded bredigite and
vancomycin-loaded 5% PLGA-coated bredigite scaffolds, respectively.

Form this work, it is finally concluded that the 10% PLGA coating is the optimal surface modification for
the vancomycin-loaded bredigite scaffolds for bone tissue-engineering and local drug delivery
applications. This assignment is due to the fact that this sample benefits from the appropriate pores
configuration, drug release kinetics, cytocompatibility and cell attachment characterized by a spread
morphology of cells with high cytoplasmic extensions (Fig. 8).

Fig. 8. FESEM micrograph of a cell cultured on the vancomycin-impregnated 10% PLGA-coated bredigite scaffold,
in which the arrows indicate cells.

4. Conclusions

In this work, bredigite (Ca7MgSi4O16) porous scaffolds were fabricated by the sponge replica method,
impregnated with vancomycin hydrochloride and coated with PLGA for bone tissue engineering. The
bare drug-loaded scaffold exhibited a one-step burst release of vancomycin, so that the relatively
entire amount of the drug loaded was released in less than 24 h. The burst release of the drug and the
fast bioresorption of bredigite were recognized to be responsible for the relatively low
cytocompatibility of this sample with respect to dental pulp stem cells. The PLGA coating, nevertheless,
altered the drug delivery kinetics characterized by the limitation of the burst drug release stage and by
the development of a sustained drug release behavior. This surface modification process also improved
the cell viability, which was attributed to the modification of the drug release and the buffering effect
of PLGA on physiological pH. The most improvement in the biological behaviors was obtained by
employing the PLGA coating deposited from the 10% PLGA-acetone solution, with the suitable
characteristics of pores for bone tissue engineering and the appropriate antibiotic release kinetics for
osteomyelitis treatment.
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